(alphaS)-alpha-氨基-苯乙酸乙酯盐酸盐(1:1) | 59410-82-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (alphaS)-alpha-氨基-苯乙酸乙酯盐酸盐(1:1)
• 英文名称: (S)-phenylglycine ethyl ester hydrochloride
• 英文别名: ethyl (2S)-2-amino-2-phenylacetate;hydrochloride
• CAS: 59410-82-1
• 化学式: C₁₀H₁₃NO₂*ClH
• 分子量: 215.68
• InChiKey: FNNXQLSKQSVNLL-FVGYRXGTSA-N

物化性质

• 熔点：
  202-204 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.67
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下保存于惰性气体中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Phg-OEt HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Phg-OEt HCl
CAS number: 59410-82-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13NO2.ClH
Molecular weight: 215.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (alphaS)-alpha-氨基-苯乙酸乙酯盐酸盐(1:1) 在 sodium hydroxide 、 三乙胺 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 4.33h， 生成 Cbz-L-苯甘氨酸
  参考文献：
  名称：

  Poststatin, a New Inhibitor of Prolyl Endopeptidase. V. Endopeptidase Inhibitory Activity of Poststatin Analogues.

  摘要：

  合成了30个波杀菌蛋白类似物，并测定了它们对脯氨酰内肽酶、人白细胞弹性蛋白酶和组织蛋白酶B的抑制活性。对内肽酶抑制活性来说，α–酮基非常重要，β–取代–β–氨基–α–氧代丙酸部分的S构型比R构型更为优越。用L–亮氨酸代替波杀菌蛋白中的D–亮氨酸得到的类似物对组织蛋白酶B具有很强的抑制活性。将芳香基团引入到P4位和将脯氨酸引入到P2位使对弹性蛋白酶的抑制活性增强。苄氧羰基–L–高苯丙氨酰–(RS)–3–氨基–2–氧代戊二酰–D–亮氨酰–L–缬氨酸对脯氨酰内肽酶的活性约为天然波杀菌蛋白的6倍。

  DOI：

  10.7164/antibiotics.49.890
• 作为产物：
  描述：

  2-氨基-2-苯基乙酸 在 盐酸 、 D(+)-10-樟脑磺酸 作用下， 生成 (alphaS)-alpha-氨基-苯乙酸乙酯盐酸盐(1:1)
  参考文献：
  名称：

  McKenzie; Wills, Journal of the Chemical Society, 1925, vol. 127, p. 284

  摘要：

  DOI：

文献信息

• Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies
  作者：Yue Dong、Xinyong Liu、Yunfei An、Min Liu、Jun Han、Bin Sun

  DOI：10.1016/j.bioorg.2020.103749

  日期：2020.6

  block the ergosterol synthesis. In this study, we designed a series of dual-target arylamides derivatives based on the analysis of active sites (SE, CYP51). Subsequently, these target compounds were synthesized, and their antifungal activity was evaluated. Most of compounds demonstrate the potent antifungal activity against multiple Candida spp. and A. fum. In particular, the antifungal activities of compounds

  由于高感染率和频繁出现的耐药性，真菌感染已成为严重的医学问题。麦角固醇是真菌细胞膜的重要结构成分，其合成酶（角鲨烯环氧酶（SE）和14α-脱甲基酶（CYP51））被认为是阻断麦角固醇合成的关键点。在这项研究中，我们基于对活性位点（SE，CYP51）的分析设计了一系列双靶芳酰胺衍生物。随后，合成这些目标化合物，并评估其抗真菌活性。大多数化合物对多种念珠菌均显示出有效的抗真菌活性。和烟熏 特别是，化合物10b和11c的抗真菌活性不仅优于阳性对照药物，但对耐药真菌也有明显的抑制作用（C.alb。Strain100，C.alb。Strain103）。因此，对其作用机理进行了进一步研究。细胞吸收和电子显微镜观察表明，目标化合物能够通过自由扩散进入真菌细胞质区域，并破坏细胞膜结构。同时，初步机制已证明它们可以通过抑制双重靶标的活性来影响麦角甾醇的合成。值得注意的是，它们在体内还表现出优异的抗真菌活性和
• [EN] THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS<br/>[FR] COMPOSES THERAPEUTIQUES DESTINES AU TRAITEMENT D'ETATS DYSLIPIDEMIQUES
  申请人：MERCK & CO INC

  公开号：WO2004011448A1

  公开（公告）日：2004-02-05

  The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

  本发明涉及式I的新LXR配体及其药用可接受的盐、酯和互变异构体，它们在治疗血脂异常状况，特别是低HDL胆固醇水平方面具有用途。
• Dicarboximide-based clathrate design. Host synthesis, inclusion formation and x-ray crystal structures of a free host and of inclusion compounds with 2- and 3- methylcyclohexanone, 3-methylcyclopentanone, butyronitrile, propan-1-ol and (?)-fenchone guests
  作者：Edwin Weber、Christiane Reutel、Concepci�n Foces-Foces、Antonio L. Llamas-Saiz

  DOI：10.1002/poc.610080306

  日期：1995.3

  Crystalline host compounds consisting of a roof-shaped dicarboxinide framework and pendant diarylethanol analogous subunits were synthesized and shown to form inclusion complexes with small organic molecules such as alcohols, amines, ketones or polar and apolar organic solvents. Clathrate efficiency and selectivity depend on the particular host structure. The crystal and molecular structures of a free

  合成了由屋顶形的二羧甲骨架和侧基二芳基乙醇类似的亚基组成的结晶主体化合物，显示出与小的有机分子（如醇，胺，酮或极性和非极性有机溶剂）形成包合物。包合物的效率和选择性取决于特定的宿主结构。游离主体化合物（2a）和包含化合物[2a·3-甲基环己酮（1：1），1a·3-甲基环戊酮（1：1），1a·2-甲基环己酮（1：1），通过x射线衍射分析确定1b·丁腈（1∶1），1b·丙-1-醇（2∶1）和1b·（-）-甲烯酮（1∶1）]。在所有结构中，羟基均参与分子内氢键，并且主体和客体分子仅通过晶格力保持。残留在主体基质中的通道和空腔足够大，可以允许来宾分子的无序或高热位移参数。所有客人的本地包装系数平均为0·42。
• Herstellung enantiomerenreiner<i>cis</i>- oder<i>trans</i>-konfigurierter 2-(<i>tert</i>-Butyl)-3-methylimidazolidin-4-one aus den Aminosäuren (<i>S</i>)-Alanin, (<i>S</i>)-Phenylalanin, (<i>R</i>)-Phenylglycin, (<i>S</i>)-Methionin und (<i>S</i>)-Valin
  作者：Reto Naef、Dieter Seebach

  DOI：10.1002/hlca.19850680117

  日期：1985.2.13

  Preparation of the Enantiomerically Pure cis- and trans-Configurated 2-(tert-Butyl)-3-methylimidazolidin-4-ones from the Amino Acids (S)-Alanine, (S)-Phenylalanine, (R)-Phenylglycine, (S)-Methionine, and (S)-Valine

  对映体纯的制备顺式-和反式-构型的2-（叔丁基）-3-甲基咪唑烷-4-酮从氨基酸（小号） -丙氨酸，（小号） -苯丙氨酸，（- [R ）-苯基甘氨酸，（小号）-蛋氨酸和（S）-缬氨酸
• [EN] THIOPHENE AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES D'ACIDE AMINE THIOPHENIQUE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：WARNER LAMBERT CO

  公开号：WO2005003115A1

  公开（公告）日：2005-01-13

  Compounds of formula (I), in which: R1 and R2, which may be identical or different, independently of each other, each represent a group selected from: hydrogen, halogen, cyano, nitro, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OR4, -NR4R5, -S(O)nR4, -C(O)R4, -CO2R4, -O-C(O)R4, -C(O)NR4R5, -NR5-C(O)R4, -NR5-SO2R4, -T-CN, -T-OR4, -T-OCF3, -T-NR4R5, -T-S(O)nR4, -T-C(O)R4, -T-CO2 R4, -T-O-C(O)R4, -T-C(O)NR4 R5, -T-NR5-C(O)R4, -T-NR5-SO2R4, -R6 and -T-R6 in which n, T, R4, R5 and R6 are as defined in the description ; m represents an integer between 0 and 4 inclusive ; p represents an integer between 0 and 4 inclusive ; q represents an integer between 0 and 4 inclusive ; R7 represents a group selected from aryl, cycloalkyl and a heterocycle, each of these groups being optionally substituted; R8 represents a group selected from carboxyl, (C1-C6)alkoxycarbonyl, (C1-C7)acyl, hydroxy(C1-C6)alkylcarbonyl, (C1-C6)alkoxy(C1-C6)alkylcarbonyl, tetrazole, amino, aminocarbonyl and amino(C1-C6)alkylcarbonyl; the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid or base, and the pharmaceutical compositions which are useful for treating pathologies associated with an inhibition of metalloproteases.

  化合物的化学式（I）中：R1和R2可以相同也可以不同，分别表示从以下选定的基团中选择的基团：氢、卤素、氰基、硝基、卤代（C1-C6）烷基、卤代（C1-C6）氧基、（C1-C6）烷基、（C2-C6）烯基、（C2-C6）炔基、-OR4、-NR4R5、-S（O）nR4、-C（O）R4、-CO2R4、-O-C（O）R4、-C（O）NR4R5、-NR5-C（O）R4、-NR5-SO2R4、-T-CN、-T-OR4、-T-OCF3、-T-NR4R5、-T-S（O）nR4、-T-C（O）R4、-T-CO2 R4、-T-O-C（O）R4、-T-C（O）NR4 R5、-T-NR5-C（O）R4、-T-NR5-SO2R4、-R6和-T-R6其中n、T、R4、R5和R6如描述中所定义；m表示0到4之间的整数；p表示0到4之间的整数；q表示0到4之间的整数；R7表示从芳基、环烷基和杂环中选择的基团，这些基团可以选择性地被取代；R8表示从羧基、（C1-C6）烷氧羰基、（C1-C7）酰基、羟基（C1-C6）烷基羰基、（C1-C6）烷氧基（C1-C6）烷基羰基、四唑基、氨基、氨基羰基和氨基（C1-C6）烷基羰基中选定的基团；其异构体及其与药用酸或碱形成的可接受的加合盐，以及用于治疗与金属蛋白酶抑制相关的病理的药物组合物。